Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis

被引：21

作者：

Strand, Vibeke ^{[1
]}

McInnes, Iain ^{[2
]}

Mease, Philip ^{[3
,4
]}

Nash, Peter ^{[5
]}

Thom, Howard ^{[6
]}

Kalyvas, Chrysostomos ^{[7
]}

Hunger, Matthias ^{[8
]}

Gandhi, Kunal ^{[9
]}

Pricop, Luminita ^{[9
]}

Jugl, Steffen ^{[10
]}

Choy, Ernest ^{[11
]}

机构：

[1] 306 Ramona Rd, Portola Valley, CA 94028 USA

[2] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Sir Graeme Davies Bldg,120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland

[3] Swedish Med Ctr, 601 Broadway,Suite 600, Seattle, WA 98122 USA

[4] Univ Washington, Dept Med, 601 Broadway,Suite 600, Seattle, WA 98122 USA

[5] Univ Queensland, Dept Med, Brisbane, Qld 4072, Australia

[6] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England

[7] Mapi, De Molen 84, NL-3995 AX Houten, Netherlands

[8] Mapi, Konrad Zuse Pl 11, D-81829 Munich, Germany

[9] Novartis Pharmaceut, Immunol & Dermatol Franchise, One Hlth Plaza,Bldg 337,B04-3B, E Hanover, NJ USA

[10] Novartis Pharma AG, Global Patient Access Immunol Hepatol & Dermatol, CH-4002 Basel, Switzerland

[11] Cardiff Univ, CREATE Ctr, Div Infect & Immun, Sect Rheumatol,Sch Med, Tenovus Bldg,Heath Pk Campus, Cardiff CF14 4XN, S Glam, Wales

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2019年 / 8卷 / 07期

关键词：

comparative effectiveness; infliximab; matching-adjusted indirect comparison; psoriatic arthritis; secukinumab; WORKING GROUP; ADALIMUMAB; RECOMMENDATIONS; METAANALYSIS;

D O I：

10.2217/cer-2018-0141

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secukinumab were matched to published aggregate data for infliximab by key baseline characteristics, with matching weights determined by logistic regression, and used to recalculate American College of Rheumatology (ACR) responses for secukinumab, for comparison with infliximab. Results: There were no differences in outcomes between secukinumab and infliximab at weeks 6/8 and 14/16. At weeks 24 and 54/52, ACR 20 responses were higher with secukinumab 150 mg than infliximab. At week 54/52, ACR 20/50 responses were higher for secukinumab 300 mg than infliximab. Conclusion: In the mid to long term, patients receiving secukinumab were more likely to achieve ACR 20/50 responses than those receiving infliximab.

引用

页码：497 / 510

页数：14

共 32 条

[1]

[Anonymous], 2016, NICE DSU TECHNICAL S

[2]

[Anonymous], 2016, HIGHLIGHTS OF PRESCRIBING INFORMATION

[3] Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J].